Inscripta, Inc. Email Format
Biotechnology ResearchCO , United States51-200 Employees
Inscripta merged with Manus in April 2025 to establish a unique end-to-end platform for scalable development, biomanufacturing, and commercialization of bioalternative products. By combining Inscripta’s advanced whole-genome engineering technologies with Manus’ proven cell factory engineering platform, biomanufacturing expertise, and commercialization capabilities, the merged company – Manus – is uniquely positioned to deliver commercial momentum and scaled profitability in next-generation industrial biotechnology.